Wounds – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Wounds – Pipeline Review, H2 2016’, provides an overview of the Wounds pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wounds, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wounds and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Wounds

The report reviews pipeline therapeutics for Wounds by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Wounds therapeutics and enlists all their major and minor projects

The report assesses Wounds therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Wounds

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Wounds

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aerpio Therapeutics Inc

AlgiPharma AS

AmpliPhi Biosciences Corp

AndroScience Corp

Aridis Pharmaceuticals LLC

Beech Tree Labs Inc

Bio3 Research Srl

Biotec Pharmacon ASA

Blueberry Therapeutics Ltd

Cellphire Inc

CorMedix Inc

Dermala Inc

Destiny Pharma Ltd

Escape Therapeutics Inc

EyeGene Inc

FibroGen Inc

GangaGen Inc

Gene Signal International SA

GlaxoSmithKline Plc

IC-MedTech Inc

Living Cell Technologies Ltd

Madam Therapeutics BV

miRagen Therapeutics Inc

NatureWise Biotech & Medicals Corp

Novan Inc

NuvOx Pharma LLC

Octapharma AG

Omeros Corp

Osiris Therapeutics Inc

Pacific Northwest Biotechnology LLC

Pharmaxis Ltd

ProMetic Life Sciences Inc

RiverTown Therapeutics Inc

RMB-Research GmbH

RXi Pharmaceuticals Corp

Sinclair Pharma Plc

SomaGenics Inc

Stratatech Corp

TGV-Laboratories

Thesan Pharmaceuticals Inc

Topadur Pharma AG

Trophogen Inc

Tumorend LLC

VBS Pharmaceuticals

viDA Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Wounds Overview 10

Therapeutics Development 11

Pipeline Products for Wounds - Overview 11

Pipeline Products for Wounds - Comparative Analysis 12

Wounds - Therapeutics under Development by Companies 13

Wounds - Therapeutics under Investigation by Universities/Institutes 17

Wounds - Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Wounds - Products under Development by Companies 23

Wounds - Products under Investigation by Universities/Institutes 28

Wounds - Companies Involved in Therapeutics Development 30

Aerpio Therapeutics Inc 30

AlgiPharma AS 31

AmpliPhi Biosciences Corp 32

AndroScience Corp 33

Aridis Pharmaceuticals LLC 34

Beech Tree Labs Inc 35

Bio3 Research Srl 36

Biotec Pharmacon ASA 37

Blueberry Therapeutics Ltd 38

Cellphire Inc 39

CorMedix Inc 40

Dermala Inc 41

Destiny Pharma Ltd 42

Escape Therapeutics Inc 43

EyeGene Inc 44

FibroGen Inc 45

GangaGen Inc 46

Gene Signal International SA 47

GlaxoSmithKline Plc 48

IC-MedTech Inc 49

Living Cell Technologies Ltd 50

Madam Therapeutics BV 51

miRagen Therapeutics Inc 52

NatureWise Biotech & Medicals Corp 53

Novan Inc 54

NuvOx Pharma LLC 55

Octapharma AG 56

Omeros Corp 57

Osiris Therapeutics Inc 58

Pacific Northwest Biotechnology LLC 59

Pharmaxis Ltd 60

ProMetic Life Sciences Inc 61

RiverTown Therapeutics Inc 62

RMB-Research GmbH 63

RXi Pharmaceuticals Corp 64

Sinclair Pharma Plc 65

SomaGenics Inc 66

Stratatech Corp 67

TGV-Laboratories 68

Thesan Pharmaceuticals Inc 69

Topadur Pharma AG 70

Trophogen Inc 71

Tumorend LLC 72

VBS Pharmaceuticals 73

viDA Therapeutics Inc 74

Wounds - Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Combination Products 76

Assessment by Target 77

Assessment by Mechanism of Action 80

Assessment by Route of Administration 83

Assessment by Molecule Type 85

Drug Profiles 87

(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 87

A-3APO - Drug Profile 88

ABSA-01 - Drug Profile 89

AKB-4924 - Drug Profile 92

ALLO-ASC - Drug Profile 93

AlloGraf - Drug Profile 94

Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 95

APO-1 - Drug Profile 96

APO-2 - Drug Profile 97

AR-101 - Drug Profile 98

Arginine Butyrate - Drug Profile 99

ARN-077 - Drug Profile 100

ASCJ-9 - Drug Profile 101

B-244 - Drug Profile 103

BB-1000 - Drug Profile 104

BDM-I - Drug Profile 105

BTL-slo - Drug Profile 107

CAR Peptide - Drug Profile 108

Cell Therapy for Chronic Wounds - Drug Profile 109

Cell Therapy for Dermatology and Immunology - Drug Profile 110

Cell Therapy for Wounds - Drug Profile 112

CM-101 - Drug Profile 113

CRMD-004 - Drug Profile 114

CTR-2 - Drug Profile 115

daprodustat - Drug Profile 116

DB-2121 - Drug Profile 119

Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 120

Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile 121

Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 122

EGS-001 - Drug Profile 123

FG-6874 - Drug Profile 124

G-3KL - Drug Profile 125

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 126

Gene Therapy to Activate HSP60 for Wounds - Drug Profile 127

GS-156 - Drug Profile 128

Human Growth Factor - Drug Profile 129

hVGF - Drug Profile 130

JM-2 - Drug Profile 131

KL-7016 - Drug Profile 132

LWnt-3a - Drug Profile 133

MG-53 - Drug Profile 134

MMP-26051 - Drug Profile 136

MMP-26052 - Drug Profile 137

molgramostim - Drug Profile 138

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 139

MRG-110 - Drug Profile 140

Mul-1867 - Drug Profile 141

NBM-67 - Drug Profile 142

ND-336 - Drug Profile 143

NTCELL - Drug Profile 144

Oligomer G for Wounds And Burns - Drug Profile 148

OTI-1011 - Drug Profile 149

OTI-1502 - Drug Profile 150

P-128 - Drug Profile 151

P-148 - Drug Profile 152

Panaecin - Drug Profile 153

perflenapent for wound healing - Drug Profile 154

Perlecan - Drug Profile 155

PGF - Drug Profile 157

plasminogen (recombinant) - Drug Profile 158

Polysaccharide for Wounds and Scars - Drug Profile 159

Protein for Diabetic Wound Healing - Drug Profile 160

Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile 161

Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 162

Protein to Activate FGF2 for Wound Healing - Drug Profile 163

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 164

PXS-4820 - Drug Profile 165

Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 166

Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 167

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 168

Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile 169

Recombinant Protein to Inhibit SEB and TSST-1 for Pulmonary Infections, Bacterial Infections, Toxic Shock and Wounds - Drug Profile 170

Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 171

RT-1740 - Drug Profile 172

SG-404 - Drug Profile 173

silver sulfadiazine - Drug Profile 174

Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile 175

Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile 176

Small Molecule to Target LGR6 for Dermatology - Drug Profile 177

Small Molecules for Staphylococcal Infections and Wounds - Drug Profile 178

Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile 179

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 180

Soluble Beta Glucan - Drug Profile 181

Statmicoll - Drug Profile 184

Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 185

Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 186

Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile 187

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 188

Thrombosomes - Drug Profile 190

Tolecine - Drug Profile 191

TOPN-53 - Drug Profile 192

TRBN-0224 - Drug Profile 193

TWB-103 - Drug Profile 195

V-2248 - Drug Profile 196

VTI-3000 Series - Drug Profile 197

WH-1 - Drug Profile 198

XF-70 - Drug Profile 199

Wounds - Dormant Projects 200

Wounds - Discontinued Products 209

Wounds - Product Development Milestones 210

Featured News & Press Releases 210

Appendix 216

Methodology 216

Coverage 216

Secondary Research 216

Primary Research 216

Expert Panel Validation 216

Contact Us 216

Disclaimer 217

List of Tables

List of Tables

Number of Products under Development for Wounds, H2 2016 18

Number of Products under Development for Wounds – Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Development by Companies, H2 2016 (Contd..1) 21

Number of Products under Development by Companies, H2 2016 (Contd..2) 22

Number of Products under Development by Companies, H2 2016 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 26

Comparative Analysis by Clinical Stage Development, H2 2016 27

Comparative Analysis by Early Stage Development, H2 2016 28

Comparative Analysis by Unknown Stage Development, H2 2016 29

Products under Development by Companies, H2 2016 30

Products under Development by Companies, H2 2016 (Contd..1) 31

Products under Development by Companies, H2 2016 (Contd..2) 32

Products under Development by Companies, H2 2016 (Contd..3) 33

Products under Development by Companies, H2 2016 (Contd..4) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36

Wounds – Pipeline by Aerpio Therapeutics Inc, H2 2016 37

Wounds – Pipeline by AlgiPharma AS, H2 2016 38

Wounds – Pipeline by AmpliPhi Biosciences Corp, H2 2016 39

Wounds – Pipeline by AndroScience Corp, H2 2016 40

Wounds – Pipeline by Aridis Pharmaceuticals LLC, H2 2016 41

Wounds – Pipeline by Beech Tree Labs Inc, H2 2016 42

Wounds – Pipeline by Bio3 Research Srl, H2 2016 43

Wounds – Pipeline by Biotec Pharmacon ASA, H2 2016 44

Wounds – Pipeline by Blueberry Therapeutics Ltd, H2 2016 45

Wounds – Pipeline by Cellphire Inc, H2 2016 46

Wounds – Pipeline by CorMedix Inc, H2 2016 47

Wounds – Pipeline by Dermala Inc, H2 2016 48

Wounds – Pipeline by Destiny Pharma Ltd, H2 2016 49

Wounds – Pipeline by Escape Therapeutics Inc, H2 2016 50

Wounds – Pipeline by EyeGene Inc, H2 2016 51

Wounds – Pipeline by FibroGen Inc, H2 2016 52

Wounds – Pipeline by GangaGen Inc, H2 2016 53

Wounds – Pipeline by Gene Signal International SA, H2 2016 54

Wounds – Pipeline by GlaxoSmithKline Plc, H2 2016 55

Wounds – Pipeline by IC-MedTech Inc, H2 2016 56

Wounds – Pipeline by Living Cell Technologies Ltd, H2 2016 57

Wounds – Pipeline by Madam Therapeutics BV, H2 2016 58

Wounds – Pipeline by miRagen Therapeutics Inc, H2 2016 59

Wounds – Pipeline by NatureWise Biotech & Medicals Corp, H2 2016 60

Wounds – Pipeline by Novan Inc, H2 2016 61

Wounds – Pipeline by NuvOx Pharma LLC, H2 2016 62

Wounds – Pipeline by Octapharma AG, H2 2016 63

Wounds – Pipeline by Omeros Corp, H2 2016 64

Wounds – Pipeline by Osiris Therapeutics Inc, H2 2016 65

Wounds – Pipeline by Pacific Northwest Biotechnology LLC, H2 2016 66

Wounds – Pipeline by Pharmaxis Ltd, H2 2016 67

Wounds – Pipeline by ProMetic Life Sciences Inc, H2 2016 68

Wounds – Pipeline by RiverTown Therapeutics Inc, H2 2016 69

Wounds – Pipeline by RMB-Research GmbH, H2 2016 70

Wounds – Pipeline by RXi Pharmaceuticals Corp, H2 2016 71

Wounds – Pipeline by Sinclair Pharma Plc, H2 2016 72

Wounds – Pipeline by SomaGenics Inc, H2 2016 73

Wounds – Pipeline by Stratatech Corp, H2 2016 74

Wounds – Pipeline by TGV-Laboratories, H2 2016 75

Wounds – Pipeline by Thesan Pharmaceuticals Inc, H2 2016 76

Wounds – Pipeline by Topadur Pharma AG, H2 2016 77

Wounds – Pipeline by Trophogen Inc, H2 2016 78

Wounds – Pipeline by Tumorend LLC, H2 2016 79

Wounds – Pipeline by VBS Pharmaceuticals, H2 2016 80

Wounds – Pipeline by viDA Therapeutics Inc, H2 2016 81

Assessment by Monotherapy Products, H2 2016 82

Assessment by Combination Products, H2 2016 83

Number of Products by Stage and Target, H2 2016 85

Number of Products by Stage and Mechanism of Action, H2 2016 88

Number of Products by Stage and Route of Administration, H2 2016 91

Number of Products by Stage and Molecule Type, H2 2016 93

Wounds – Dormant Projects, H2 2016 207

Wounds – Dormant Projects (Contd..1), H2 2016 208

Wounds – Dormant Projects (Contd..2), H2 2016 209

Wounds – Dormant Projects (Contd..3), H2 2016 210

Wounds – Dormant Projects (Contd..4), H2 2016 211

Wounds – Dormant Projects (Contd..5), H2 2016 212

Wounds – Dormant Projects (Contd..6), H2 2016 213

Wounds – Dormant Projects (Contd..7), H2 2016 214

Wounds – Dormant Projects (Contd..8), H2 2016 215

Wounds – Discontinued Products, H2 2016 216

List of Figures

List of Figures

Number of Products under Development for Wounds, H2 2016 18

Number of Products under Development for Wounds – Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 27

Comparative Analysis by Early Stage Products, H2 2016 28

Assessment by Monotherapy Products, H2 2016 82

Number of Products by Top 10 Targets, H2 2016 84

Number of Products by Stage and Top 10 Targets, H2 2016 84

Number of Products by Top 10 Mechanism of Actions, H2 2016 87

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 87

Number of Products by Top 10 Routes of Administration, H2 2016 90

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 90

Number of Products by Top 10 Molecule Types, H2 2016 92

Number of Products by Stage and Top 10 Molecule Types, H2 2016 92

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports